NCT04475432Phase 2, phase 3Completed

Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis

Study sponsor: Tarsus Pharmaceuticals, Inc. · TARS

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2021-05-04Actual

Enrollment · participants421Actual

Source updated2023-12-21Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Blepharitis

Treatments or interventions studied

TP-03, 0.25%DrugAlso known as Lotilaner ophthalmic solution, 0.25%
TP-03 VehicleDrug

Primary outcomes · main study measures

Read the study measures

measure: Proportion of Participants Cured Based on a Collarette Score at Day 43.; description: The proportion of participants cured where cure is defined as 0-2 lashes with collarettes on the upper eyelid of the analysis eye. The primary outcome analysis is the combined result from 20 analyses each with missing data imputed. Missing data were imputed per the method described in the SAP. The least square mean is computed from the result of the 20 analyses with imputed missing values.; timeFrame: 43 days

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history